Source: BioPortfolio

Tedor Pharma: CDMO Tedor Pharma recapitalizes following multimillion dollar investment

The newlyformed investment firm DORA Ventures has recapitalized Tedor Pharma which recently completed a multimilliondollar expansion of its manufacturing capabilities.

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Doug Drysdale's photo - President & CEO of Tedor

President & CEO

Doug Drysdale

CEO Approval Rating

86/100

Read more